EMADOC-1700519818-2111879

European Medicines Agency decision

EMEA-002828-PIP01-20

of 16 May 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for firsocostat / cilofexor in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMEA-002828-PIP01-20

of 16 May 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for firsocostat / cilofexor in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Gilead Sciences International Limited on 17 April 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 March 2025, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for firsocostat / cilofexor, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for firsocostat / cilofexor, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for firsocostat / cilofexor, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Gilead Sciences International Limited, Flowers Building, Granta Park, Great Abington, Cambridge, CB21 6GT, United Kingdom.

EMADOC-1700519818-1834577
Amsterdam, 28 March 2025

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-002828-PIP01-20

Scope of the application

Active substance(s):

Cilofexor / firsocostat

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of metabolic dysfunction-associated steatohepatitis

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Gilead Sciences International Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Limited submitted for agreement to the European Medicines Agency on 17 April 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 26 May 2020.

Supplementary information was provided by the applicant on 18 December 2024. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of metabolic dysfunction-associated steatohepatitis

The waiver applies to:

- the paediatric population from birth to less than 8 years of age;
- film-coated tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of metabolic dysfunction-associated steatohepatitis

2.1.1. Indication(s) targeted by the PIP

Treatment of metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis in adolescents and children 8 years of age and older

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 8 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Area	**Description**
Quality-related studies	**Study 1** Development of an age-appropriate tablet strength suitable for use in children from 8 years of age.
Non-clinical studies	Not applicable
Clinical studies	**Study 2** Randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of cilofexor/firsocostat (CILO/FIR) fixed-dose combination (FDC) in paediatric participants aged from 8 years to less than 18 years with MASH and fibrosis. The study will consist of a PK lead-in phase and a treatment phase.
Modelling and simulation analyses	**Study 3**

	Population pharmacokinetic (Pop-PK) model to evaluate the use of cilofexor/firsocostat (CILO/FIR) fixed-dose combination in children and adolescents from 8 years to less than 18 years of age.
Other studies	Not applicable
Extrapolation plan	Studies 2 and 3 are part of an extrapolation plan covering the paediatric population from 8 years to less than 18 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2034
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.